These findings suggest that PINK1 plays a crucial role in modulating mitochondrial dynamics that confer therapeutic resistance, highlighting its potential as a therapeutic target for overcoming olaparib resistance in prostate cancer. This evidence concerns the gene PINK1 and prostate carcinoma.